Antiagregação e anticoagulação na intervenção coronária
27227
30. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparina in acute
coronary syndromes. N Engl J Med. 2006;354:1464‑76.
31. Bellemain‑Appaix A, O’Connor SA, Silvain J, et al. Association of Clopidogrel Pretreatment
With Mortality, Cardiovascular Events, and Major Bleeding Among Patients Undergoing
Percutaneous Coronary Intervention: A Systematic Review and Meta‑analysis. JAMA.
2012;308:2507–2516.
32. Puma JA, Banko LT, Pieper KS, et al. Clinical characteristics predict benefits from eptifibatide
therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet
IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial. J Am Coll Cardiol . 2006; 47:715‑8.
33. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long‑term efficacy of bivalirudin and provisional
glycoprotein IIb/IIIa blockade vs.heparin and planned glycoprotein IIb/IIIa blockade during
percutaneous coronary revascularization: REPLACE‑2 randomized trial. JAMA. 2004;292:696–
703.
34. Montalescot G, Gallo R, White HD, et al. Enoxaparin vs. unfractionated heparin in elective
percutaneous coronary intervention 1‑year results from the STEEPLE (SafeTy and efficacy
of enoxaparin in percutaneous coronary intervention patients, an international randomized
evaluation) trial. JACC Cardiovasc Interv. 2009;2:1083–1091.
35. Airoldi F, Colombo A, Morici N, et al. Incidence and preditors of drug‑eluting stent thrombosis
during and after discontinuation of thienopyridine treatment. Circulation. 2007;116:745
36. Lüscher TF, Steffel J, Eberli FR, et al. Drug‑eluting stent and coronary thrombosis: biological
mechanisms and clinical implications. Circulation. 2007; 115:1051‑58.
37. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of
drug‑eluting stents. N Engl J Med. 2007; 356:1020.
38. David P. Faxon.Very late stent thrombosis and late target lesion revascularization. Circulation.
2012;125:562‑4.
39. Antithrombotic Trialists’ Collaboration. Collaborative meta‑analysis of randomised trials
of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk
patients. BMJ. 2002; 324:71.
40. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after
drug‑eluting stents. N Engl J Med. 2014; 371:2155.
41. Bonaca MP, Bhatt DL, Cohen M, et al. Long‑term use of ticagrelor in patients with prior
myocardial infarction. N Engl J Med. 2015; 372:1791‑1800.
